-
Je něco špatně v tomto záznamu ?
Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy
AK. Wani, R. Singh, N. Akhtar, A. Prakash, E. Nepovimova, P. Oleksak, Z. Chrienova, S. Alomar, C. Chopra, K. Kuca
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, přehledy
- MeSH
- fosfatidylinositol-3-kinasy * metabolismus MeSH
- inhibitory fosfoinositid-3-kinasy farmakologie terapeutické užití MeSH
- inhibitory proteinkinas farmakologie chemie terapeutické užití MeSH
- lidé MeSH
- mTOR inhibitory farmakologie terapeutické užití MeSH
- protinádorové látky * farmakologie chemie terapeutické užití MeSH
- protoonkogenní proteiny c-akt * metabolismus antagonisté a inhibitory MeSH
- sarkom * farmakoterapie metabolismus patologie MeSH
- signální transdukce * účinky léků MeSH
- TOR serin-threoninkinasy * antagonisté a inhibitory metabolismus MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.
Biomedical Research Center University Hospital Hradec Kralove Hradec Králové Czechia
Department of Biochemistry and Biophysics University of North Carolina Chapel Hill NC 27599 USA
Department of Chemistry Faculty of Science University of Hradec Králové Hradec Králové Czechia
King Saud University Zoology Department College of Science Riyadh 11451 Saudi Arabia
School of Bioengineering and Biosciences Lovely Professional University Jalandhar Punjab India
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24020049
- 003
- CZ-PrNML
- 005
- 20241024110913.0
- 007
- ta
- 008
- 241015s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/0113895575270904231129062137 $2 doi
- 035 __
- $a (PubMed)38265369
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Wani, Atif Khurshid $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India $1 https://orcid.org/0000000288201231
- 245 10
- $a Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy / $c AK. Wani, R. Singh, N. Akhtar, A. Prakash, E. Nepovimova, P. Oleksak, Z. Chrienova, S. Alomar, C. Chopra, K. Kuca
- 520 9_
- $a Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a TOR serin-threoninkinasy $x antagonisté a inhibitory $x metabolismus $7 D058570
- 650 12
- $a sarkom $x farmakoterapie $x metabolismus $x patologie $7 D012509
- 650 12
- $a signální transdukce $x účinky léků $7 D015398
- 650 12
- $a protoonkogenní proteiny c-akt $x metabolismus $x antagonisté a inhibitory $7 D051057
- 650 12
- $a fosfatidylinositol-3-kinasy $x metabolismus $7 D019869
- 650 12
- $a protinádorové látky $x farmakologie $x chemie $x terapeutické užití $7 D000970
- 650 _2
- $a inhibitory fosfoinositid-3-kinasy $x farmakologie $x terapeutické užití $7 D000081082
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a mTOR inhibitory $x farmakologie $x terapeutické užití $7 D000091203
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $x chemie $x terapeutické užití $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Singh, Reena $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India
- 700 1_
- $a Akhtar, Nahid $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India
- 700 1_
- $a Prakash, Ajit $u Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC 27599, USA $1 https://orcid.org/0000000176280457
- 700 1_
- $a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia $1 https://orcid.org/000000030281246X $7 xx0224758
- 700 1_
- $a Oleksak, Patrik $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia
- 700 1_
- $a Chrienova, Zofia $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia
- 700 1_
- $a Alomar, Suliman $u King Saud University, Zoology Department, College of Science, Riyadh, 11451, Saudi Arabia
- 700 1_
- $a Chopra, Chirag $u School of Bioengineering and Biosciences, Lovely Professional University, Jalandhar (144411), Punjab, India
- 700 1_
- $a Kuca, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Králové, Hradec Králové, Czechia $u Biomedical Research Center, University Hospital Hradec Kralove, Hradec Králové, Czechia $1 https://orcid.org/0000000196641109 $7 xx0041831
- 773 0_
- $w MED00008043 $t Mini reviews in medicinal chemistry $x 1875-5607 $g Roč. 24, č. 16 (2024), s. 1496-1520
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38265369 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110907 $b ABA008
- 999 __
- $a ok $b bmc $g 2202343 $s 1232022
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 24 $c 16 $d 1496-1520 $e - $i 1875-5607 $m Mini reviews in medicinal chemistry $n Mini Rev Med Chem $x MED00008043
- LZP __
- $a Pubmed-20241015